source
- Servier’s $1.5 billion muscular dystrophy drug sevasemten fails pivotal trialServier announced that its experimental muscular dystrophy therapy sevasemten did not meet its goals in a pivotal Phase III study. The trial, named GRAND CANYON, evaluated the drug’s ability to im…
- Compact Medical issues recall and updated instructions for ButterflyBVM bag-valve-mask resuscitators due to bellows holesThe FDA's Center for Devices and Radiological Health has issued an early alert about a potential high‑risk problem with certain Compact Medical ButterflyBVM bag‑valve‑mask devices. Compact Medical…